

Alliance for clinical trials in oncology (ALLIANCE) trial A
chemotherapy vs. chemotherapy plus hypofractionated
resectable adenocarcinoma of the head of the pancreas

BMC Cancer

17, 505

DOI: [10.1186/s12885-017-3441-z](https://doi.org/10.1186/s12885-017-3441-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?. <i>Annals of Surgery</i> , 2018, 268, 223-224.	2.1	6
2	Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. <i>ESMO Open</i> , 2018, 3, e000282.	2.0	21
3	How to treat borderline resectable pancreatic cancer: current challenges and future directions. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 205-213.	0.6	5
4	Medical oncology and pancreatic cancer: what the radiologist needs to know. <i>Abdominal Radiology</i> , 2018, 43, 383-392.	1.0	2
5	Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. <i>Journal of Surgical Oncology</i> , 2018, 117, 1648-1654.	0.8	18
6	Dosimetric analysis of stereotactic body radiation therapy for pancreatic cancer using MR-guided Tri-60Co unit, MR-guided LINAC, and conventional LINAC-based plans. <i>Practical Radiation Oncology</i> , 2018, 8, e312-e321.	1.1	16
7	The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. <i>Abdominal Radiology</i> , 2018, 43, 393-403.	1.0	6
8	Recent advances in radiation therapy of pancreatic cancer. <i>F1000Research</i> , 2018, 7, 1931.	0.8	12
9	Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 601-610.	0.6	5
10	Contemporary Management of Localized Resectable Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 24.	1.7	62
11	A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy. <i>Hpb</i> , 2019, 21, 204-211.	0.1	3
12	Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 1205.	1.0	7
13	Perioperative Gemcitabine+ Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 4489-4497.	0.7	19
14	Better Defining the Role of Total Neoadjuvant Radiation: Changing Paradigms in Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3701-3708.	0.7	18
15	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	1.4	144
16	Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. <i>Frontiers in Oncology</i> , 2019, 9, 1085.	1.3	48
17	Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 606-617.	0.4	21
18	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332.	1.1	121

#	ARTICLE	IF	CITATIONS
19	Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma". <i>Annals of Surgical Oncology</i> , 2019, 26, 4175-4177.	0.7	0
20	Perioperative Clinical Trials for Pancreatic Cancer in the National Clinical Trials Network. <i>Annals of Surgical Oncology</i> , 2019, 26, 4173-4174.	0.7	0
21	Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?. <i>Annals of Surgical Oncology</i> , 2019, 26, 1596-1597.	0.7	2
22	Borderline resectable pancreatic cancer "At the crossroads of precision medicine. <i>Cancer</i> , 2019, 125, 1584-1587.	2.0	10
23	New Perspective in Pancreatic Cancer. , 2019, , 151-161.		0
24	Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. <i>Journal of Surgical Oncology</i> , 2019, 120, 262-269.	0.8	18
25	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	3.0	223
26	Cutting-edge strategies for borderline resectable pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 368-372.	1.2	15
27	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. <i>Cancers</i> , 2019, 11, 278.	1.7	31
28	Integrating radiation oncology into the management of pancreatic cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2019, 51, 139-145.	0.3	2
29	SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. <i>Biochemical and Biophysical Research Communications</i> , 2019, 510, 508-514.	1.0	56
30	Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 216-222.	0.5	56
31	Advances in the Treatment of Pancreatic Cancer. , 2019, , .		1
32	Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	19
33	A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy. <i>PLoS ONE</i> , 2019, 14, e0227305.	1.1	1
34	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 913-919.	0.5	7
35	Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. <i>Pancreas</i> , 2019, 48, 837-843.	0.5	22
36	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. <i>Annals of Surgery</i> , 2019, 270, 400-413.	2.1	113

#	ARTICLE	IF	CITATIONS
37	Adjuvant and neoadjuvant therapy for pancreatic cancer. <i>Journal of Pancreatology</i> , 2019, 2, 100-106.	0.3	26
38	Improving Outcomes After Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): As Always, it is All About Patient Selection. <i>Annals of Surgical Oncology</i> , 2019, 26, 703-704.	0.7	1
39	Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1401-1413.	0.9	7
40	Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 112-121.	0.9	54
41	Setup Management for Stereotactic Body Radiation Therapy of Patients With Pancreatic Cancer Treated via the Breath-Hold Technique. <i>Practical Radiation Oncology</i> , 2020, 10, e280-e289.	1.1	8
42	Update on Management Periampullary/Pancreatic Head Cancer. <i>Indian Journal of Surgery</i> , 2020, , 1.	0.2	1
43	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	1.1	41
44	Novel Radiotherapy Technologies in the Treatment of Gastrointestinal Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 29-43.	0.9	2
45	Pancreas SBRT: Who, What, When, Where, and How. <i>Practical Radiation Oncology</i> , 2020, 10, 183-185.	1.1	12
46	Comparison of Radiation Treatment Volumes for Borderline Resectable Pancreatic Cancer in Contemporary Clinical Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 648-653.	0.6	5
47	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	157.7	237
48	Neoadjuvant Therapy. <i>Advances in Surgery</i> , 2020, 54, 49-68.	0.6	5
49	Defining and Treating Borderline Resectable Pancreatic Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 71.	1.3	11
50	Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. <i>Cancers</i> , 2020, 12, 2487.	1.7	7
51	Surgical Outcome Results From SWOG S1505. <i>Annals of Surgery</i> , 2020, 272, 481-486.	2.1	155
52	The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3703.	1.7	13
53	Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. <i>British Journal of Cancer</i> , 2020, 123, 362-368.	2.9	29
54	Optimal timing and treatment strategy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 457-468.	0.8	21

#	ARTICLE	IF	CITATIONS
55	ASO Author Reflections: Serum CA19-9 Utility in Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 2015-2016.	0.7	1
56	Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy. <i>Acta Oncologica</i> , 2020, 59, 944-948.	0.8	1
57	Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. <i>BMC Cancer</i> , 2020, 20, 203.	1.1	12
58	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. <i>Cancers</i> , 2020, 12, 1729.	1.7	26
59	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	1.3	68
60	A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation in pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1499-1505.	1.2	15
61	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. <i>Surgery</i> , 2020, 167, 803-811.	1.0	32
62	Response to Preoperative Therapy in Localized Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 516.	1.3	16
63	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 1129.	1.0	83
64	CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3950-3960.	0.7	30
65	Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2961-2971.	0.7	8
66	Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition. <i>Cancers</i> , 2020, 12, 882.	1.7	6
67	Gastrointestinal. , 2021, , 135-144.e6.		0
68	SPARC, a phase-I trial of preoperative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 278-284.	0.3	11
69	Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 843-848.	0.9	11
70	Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 134-147.	1.1	112
71	Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 74-79.	0.6	3
72	Management of Locally Advanced Pancreatic Cancer. <i>Annals of Surgery</i> , 2021, 273, 1173-1181.	2.1	47

#	ARTICLE	IF	CITATIONS
73	Patterns of Recurrence After Surgery for Pancreatic Cancer. , 2021, , 1153-1168.		1
74	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2275-2286.	0.6	4
75	Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database. <i>Surgery Open Science</i> , 2021, 3, 22-28.	0.5	7
76	Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1514-1520.	0.7	11
77	Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 15-23.	0.9	8
78	Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 6790-6802.	0.7	14
79	ASO Author Reflections: Postoperative Chemotherapy After Neoadjuvant Therapy and Pancreatectomy for Pancreatic Cancer: Balancing Patient Physiology and Disease Biology. <i>Annals of Surgical Oncology</i> , 2021, 28, 6803-6804.	0.7	0
80	Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 1432-1440.	0.8	20
81	Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. <i>Journal of Surgical Oncology</i> , 2021, 123, 1395-1404.	0.8	2
82	Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1423-1431.	0.8	4
85	Achieving â€œMarginal Gainsâ€™ to Optimise Outcomes in Resectable Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 1669.	1.7	4
86	Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 206-216.	0.4	27
87	The Landmark Series: Preoperative Therapy for Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 4104-4129.	0.7	17
88	High Dose per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1-10.	0.4	60
89	Radioprotective Effects of Allium jesdianum Extract on Reduction of Pancrease Damages Following ¹³¹ I-Radiation through Down-regulation of Apoptotic Genes, Antioxidants Regulation, and Suppression of Inflammatory Markers. <i>Jundishapur Journal of Natural Pharmaceutical Products</i> , 2021, 16, .	0.3	0
90	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8297-8308.	0.7	19
91	Borderline resectable pancreatic cancer: Certainties and controversies. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 516-528.	0.8	6
92	Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 354-363.	0.7	9

#	ARTICLE	IF	CITATIONS
93	Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer. Indian Journal of Surgical Oncology, 0, , 1.	0.3	0
94	Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era. American Surgeon, 2021, 87, 1386-1395.	0.4	3
95	Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis. Translational Oncology, 2021, 14, 101139.	1.7	1
96	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	1.1	12
98	Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2023, 30, 111-121.	1.4	7
99	Pancreas cancer trials for early stage disease: Surgeons leading therapeutic cooperative group trials. Journal of Surgical Oncology, 2021, , .	0.8	1
100	Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2021, 326, 851.	3.8	658
101	Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 719-730.	0.6	4
103	Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Advances in Radiation Oncology, 2021, 6, 100763.	0.6	19
104	Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?. Annals of Surgical Oncology, 2021, 28, 1884-1886.	0.7	4
106	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. Journal of Gastroenterology, 2020, 55, 369-382.	2.3	48
107	Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Annals of Surgery, 2022, 276, e502-e509.	2.1	6
108	Recent advances in the treatment of pancreatic cancer. F1000Research, 2020, 9, 131.	0.8	52
109	Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents. Gut and Liver, 2020, 14, 269-273.	1.4	23
110	Disease Site-Specific Guidelines for Curative Radiation Treatment During "Limited Surgery" and "Hospital Avoidance": A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic. Cureus, 2020, 12, e8190.	0.2	7
111	Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 5168.	1.7	1
112	Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma. Annals of Surgery, 2022, 275, 415-421.	2.1	9
113	Treatment Sequencing for Resectable Disease. , 2019, , 47-53.		0

#	ARTICLE	IF	CITATIONS
114	Resurgence of role of radiotherapy in neoadjuvant treatment of pancreatic cancer. <i>Journal of Current Oncology</i> , 2019, 2, 19.	0.2	0
115	Neoadjuvant Chemoradiation for Localized Pancreatic Cancer. , 2019, , 85-96.		0
116	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
117	The role of radiation for pancreatic adenocarcinoma. <i>Journal of Pancreatology</i> , 2020, 3, 72-80.	0.3	6
118	Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 160, 140-149.	1.3	90
119	PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. <i>BMC Cancer</i> , 2022, 22, 14.	1.1	5
120	Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma. <i>PeerJ</i> , 2022, 9, e12736.	0.9	1
121	Elective Target Coverage for Pancreatic Cancer: When Less Does Not Clearly Achieve More. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 143-145.	0.4	7
122	Radiation therapy in borderline resectable pancreatic cancer: A review. <i>Surgery</i> , 2022, 172, 284-290.	1.0	4
123	Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1356-1361.	0.5	11
124	Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical Tumor Volume for Pancreatic Ductal Adenocarcinoma of the Head: The "Triangle Volume". <i>Practical Radiation Oncology</i> , 2022, 12, 215-225.	1.1	6
125	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. <i>Annals of Surgical Oncology</i> , 2022, 29, 2456-2468.	0.7	12
127	Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review. <i>Journal of Gastrointestinal Oncology</i> , 2021, 13, 0-0.	0.6	0
128	Predictors of outcome in patients receiving stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancers. <i>International Journal of Hepatobiliary and Pancreatic Diseases</i> , 2022, 12, 1-9.	0.2	0
129	The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2022, 51, 100-105.	0.5	0
130	Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. <i>BMC Cancer</i> , 2022, 22, 174.	1.1	3
131	Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2022, 14, 1166.	1.7	3
132	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 744161.	1.3	5

#	ARTICLE	IF	CITATIONS
135	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	10
136	Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice. <i>Frontiers in Oncology</i> , 2021, 11, 791946.	1.3	1
137	Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?. <i>Life</i> , 2022, 12, 465.	1.1	3
138	Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. <i>Advances in Oncology</i> , 2022, 2, 35-45.	0.1	0
139	Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. <i>Annals of Surgical Oncology</i> , 2022, 29, 6015-6028.	0.7	6
140	Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer – an analysis of the Swedish national pancreatic cancer registry. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1361-1366.	0.6	3
141	Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. <i>Pancreatology</i> , 2022, 22, 741-748.	0.5	8
142	Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol. <i>BMJ Open</i> , 2022, 12, e050558.	0.8	1
143	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 783-791.e1.	2.3	16
144	Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. <i>Journal of Surgical Research</i> , 2022, 280, 543-550.	0.8	5
145	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
146	Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for advanced pancreatic and periampullary adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
147	Management of Resectable and Borderline Resectable Disease: <i>Radiation Oncology</i> . , 2022, , 153-171.		0
148	Management of Locally Advanced/Metastatic Disease: <i>Radiation Oncology</i> . , 2022, , 107-124.		0
149	Management of Resectable and Borderline Resectable Disease: <i>Medical Oncology</i> . , 2022, , 139-151.		0
150	Patient Reported Outcomes and Quality of Life. , 2022, , 351-373.		0
151	Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer – A Critical Review and Practical Consideration. <i>Biomedicines</i> , 2022, 10, 2480.	1.4	6
152	Comments on National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version). <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 637-643.	0.7	1

#	ARTICLE	IF	CITATIONS
153	Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. International Journal of Molecular Sciences, 2023, 24, 3559.	1.8	5
154	Oncolytic adenoviruses and the treatment of pancreatic cancer: a review of clinical trials. Journal of Cancer Research and Clinical Oncology, 2023, 149, 8117-8129.	1.2	2
155	CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Annals of Surgical Oncology, 2023, 30, 3013-3021.	0.7	3
156	Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm, 2023, 4, .	3.1	9
157	Preoperative downstaging of pancreatic cancer is associated with improved survival after multi-agent chemotherapy, but not after radiation. Surgical Oncology, 2023, 48, 101939.	0.8	0
158	FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Annals of Surgical Oncology, 2023, 30, 4417-4428.	0.7	10
159	Why the Treatment Sequence Matters: Interplay Between Chemotherapy Cycles received, Cumulative dose Intensity, and Survival in Resected Early-Stage Pancreas Cancer. Annals of Surgery, 0, Publish Ahead of Print, .	2.1	3
164	Radiation Therapy for Pancreatic Cancer: Current and Evolving Paradigms. , 2023, , 37-55.		0